S&P rates Octapharma BB+

Standard & Poor's said it assigned a BB+ long-term corporate credit rating to Octapharma Nordic AB.

The outlook is stable.

Rating constraints are Octapharma's relatively small size and its sole focus on plasma fractionation, according to the agency.

The rating is underpinned by the industry's healthy growth prospects and barriers to entry, S&P said. Support also stems from Octapharma's conservative financial policy, which provides comfortable financial flexibility, the agency said.

Leverage exceeding an adjusted debt-to-EBITDA ratio of 2 times could put pressure on the rating, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.